

RUBY QC INVESTMENT HOLDINGS PTE. LTD.

("the Company")
(Company Registration No. 201905580M)
(Incorporated in the Republic of Singapore)

Date: 29 May, 2024

To,

Akums Drugs and Pharmaceuticals Limited,
304 Mohan Place, Saraswati Vihar
Delhi 110 034, India

Dear Sir/ Madam,

Re: Proposed initial public offering of equity shares of ₹2 each (the "Equity Shares") of Akums Drugs and Pharmaceuticals Limited (the "Company", and such initial public offering, the "Offer")

We, Ruby QC Investment Holdings Pte. Ltd. had entered into a shareholders' agreement with the Company, Sanjeev Jain and Sandeep Jain (collectively, the "Parties") dated October 3, 2019 (the "SHA"), read with the waiver cum amendment agreement dated February 9, 2024 and the Undertaking to the SHA dated May 15, 2024 in order to record the terms and conditions in respect of the management, governance and control of the affairs of the Company.

We hereby confirm that with effect from 29 May, 2024, we will waive our rights under Clause 8.10 (ii) of the SHA, which requires the Company to buy-back the Equity Securities in accordance with the terms of the SHA and such rights shall be of no further force or effect without any further act or deed required by any Party.

The waiver effected hereunder in respect of the relevant provisions of the SHA shall also be deemed to be a waiver under the corresponding provisions of the Articles of Association.

This letter may be relied on by the BRLMs and the legal advisors in relation to the Offer. We also authorize you to deliver this letter to SEBI and any other regulatory authorities and consent to the inclusion of this letter in the Offer documents, as may be required.

Yours faithfully,

For and on behalf of Ruby QC Investment Holdings Pte. Ltd



Name: Abrar Mir
Designation: Director